Rijnstate: Difference between revisions
From Beacon
| Line 37: | Line 37: | ||
Diagnostics: breast cancer https://www.rijnstate.nl/aandoening-en-behandeling/borstkanker/hoe-onderzoeken-we-u/ and https://www.rijnstate.nl/aandoening-en-behandeling/borstkanker/rijnstate-mammapoli/up-to-date-apparatuur/ | Diagnostics: breast cancer https://www.rijnstate.nl/aandoening-en-behandeling/borstkanker/hoe-onderzoeken-we-u/ and https://www.rijnstate.nl/aandoening-en-behandeling/borstkanker/rijnstate-mammapoli/up-to-date-apparatuur/ | ||
colon cancer https://www.rijnstate.nl/aandoening-en-behandeling/darmkanker/hoe-onderzoeken-we-u/ | colon cancer https://www.rijnstate.nl/aandoening-en-behandeling/darmkanker/hoe-onderzoeken-we-u/ | ||
lung cancer https://www.rijnstate.nl/aandoening-en-behandeling/longkanker/hoe-onderzoeken-we-u/ | |||
Treatment: Surgery with Da Vinci robot https://www.rijnstate.nl/robotchirurgie | Treatment: Surgery with Da Vinci robot https://www.rijnstate.nl/robotchirurgie | ||
lung cancer https://www.rijnstate.nl/aandoening-en-behandeling/longkanker/welke-behandelingen-zijn-er/ | |||
Skin cancer https://www.rijnstate.nl/huidkanker | Skin cancer https://www.rijnstate.nl/huidkanker | ||
Remove bladder https://www.rijnstate.nl/aandoening-en-behandeling/blaaskanker/urineblaas-verwijderen/ | Remove bladder https://www.rijnstate.nl/aandoening-en-behandeling/blaaskanker/urineblaas-verwijderen/ | ||
Revision as of 23:26, 31 May 2023
Trials
Experts
Department of Medical Oncology
Learning Resources
Novel Therapies and Diagnostic Methods
Resource: Patient Journey App
Primary purpose: Provide patients will all important information about their patient journey, clearly displayed in a personal timeline.
Additional information: Information [1].
Resource: Cancer in Young Adults
Primary purpose: Provide support for adolescents and young adults with cancer.
Additional information: Information [2].
Resource: Cancer in the Elderly
Primary purpose: Provide support for the elderly with cancer.
Additional information: Information [3].
